Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

Mylan launches first generic transdermal contraceptive patch

Mylan Pharmaceutical's Xulane is the first generic contraceptive transdermal patch to hit the market, marking another milestone for the delivery technology.

Flat sales mask busy quarter for J&J med tech biz

At $7.1 billion in revenue, the balance sheet shows no changes in quarterly sales at Johnson & Johnson's medical devices and diagnostics division, but the unit experienced shifts of other sorts during the first quarter of 2014.

New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast

Weak consumer sales and flat medical device and diagnostics sales didn't stop Johnson & Johnson from trouncing analyst estimates Monday--or from raising its guidance for the year. A lineup of hot new meds powered the drug giant's first-quarter performance, helping pharma sales climb nearly 11% to $7.5 billion.

J&J axes a late-stage Botox rival, chopping project staffers

J&J says that it is discontinuing work on the neurotoxin program for PurTox, its long-acting successor to Botox, even though its Mentor subsidiary has wrapped three late-stage studies on the aesthetic therapy for smoothing out facial wrinkles.

J&J teams with Scripps on a new Big Pharma/biotech spinoff matchmaking effort

Scripps' two big research outfits in California and Florida have allied themselves with the J&J Innovation Center in Menlo Park, CA, in an effort designed to take some of their early-stage breakthroughs and spin off new development programs, looking to kick-start a few biotech startups and Big Pharma match-ups along the way.

After burning up $349M, CymaBay aims for Nasdaq as IPOs get shaky

Three years ago, Sanofi walked away from a $375 million diabetes partnership with Metabolex, which had just salved the wound with a new pact with J&J. Now, operating under a new name--CymaBay--and armed with a fresh $38 million raise from late last year, the small biotech is floating plans for a $30 million IPO, looking to cash in on the lingering biotech boom.

Bayer, J&J beef up Xarelto research to keep market-share gains coming

Johnson & Johnson and Bayer's Xarelto made its way to the front of the new-age anticoagulant pack not long after hitting the U.S. market, gaining ground from rival Pradaxa to head what has since become a three-horse race. And that's ground its makers aren't ready to cede.

J&J says BabyCenter beats Facebook and Twitter for intelligence-gathering

A Johnson & Johnson number cruncher says nuggets of marketing gold are waiting to be found on its parenting site BabyCenter.

J&J sifts marketing nuggets from Mom's BabyCenter posts

Johnson & Johnson is using a research panel of 50,000 consumers, together with sharing-minded mothers on its parenting site BabyCenter, to flag ideas and catchphrases that resonate with moms.

Jury partially faults J&J in another vaginal mesh trial verdict

Johnson & Johnson's Ethicon arm has been ordered to pay $1.2 million in damages in a trial alleging it produced faulty vaginal mesh that was implanted into a 64-year-old woman.